Navigation Links
Iomai Announces Year-End 2007 Financial Results and Business Progress
Date:3/6/2008

Conference Call at 1:30 p.m. Eastern Time Today

GAITHERSBURG, Md., March 6 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today reported financial results and corporate progress for the full year ended December 31, 2007.

"In the past few months, we have further demonstrated that Iomai's vaccine and immunostimulant patches can be safely and effectively self-applied," said Stanley C. Erck, president and chief executive officer of Iomai. "This lays the foundation for a revolution in the way vaccination is approached. Rather than shots at a doctor's office or travel clinic, we believe we have a platform that makes possible a vaccine that could be mailed to consumers and self-applied."

"2007 was a groundbreaking year for Iomai, with the positive results from the Phase 2 field study of our travelers' diarrhea vaccine and the $128 million government contract to fund the development of our adjuvant patch for pandemic influenza," continued Mr. Erck. "This year, we hope to build on those achievements by pursuing a partnering deal, announcing results from the Phase 1/2 trial of our adjuvant patch for pandemic influenza and preparing to conduct a pivotal Phase 3 trial for our travelers' diarrhea vaccine in 2009."

Full-Year and Fourth Quarter 2007 Financial Results

For the full year ended Dec. 31, 2007, Iomai reported a net loss available to common stockholders of $28.3 million, or $1.16 per share, compared to a net loss of $32.3 million, or $2.03 per share, for the year ended Dec. 31, 2006. The lower net loss per share in 2007 was attributable to increased revenues principally under our Department of Health and Human Services ("DHHS") contract, which was awarded in January 2007 and the increase
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
2. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
3. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
4. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
5. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
6. Dragon announces new product launch; increase in annual production output capacity
7. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
8. China Yingxia International Announces Q4 and FY 2007 Estimates
9. Bristol-Myers Squibb Announces Dividend
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
11. Maxygen Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
(Date:3/3/2015)... March 03, 2015 BlueInGreen ... to their international sales network. The business venture ... technology to Canada’s Atlantic Provinces, exclusively through Resource ... as one of Canada’s premiere manufacturing representative firms, ... the municipal water and wastewater markets. More information ...
(Date:3/3/2015)... The winners of awards for supply chain resilience ... Global Supply Chain Resiliency Council (GSCRC) at the ... 25th, 2015, at the Hyatt Regency in Santa Clara, ... supply chain risk management and resiliency practitioners with luminaries ... opportunities to collaborate, develop and share best practices, and ...
(Date:3/3/2015)... SAN CARLOS, Calif. , March 3, 2015 /PRNewswire/ ... with expertise in drug-disease modeling and simulation research, today ... during the 2015 American Society for Clinical Pharmacology and ... March 3-7 2015.   Logo - ... and Rosa will present a poster describing a ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... 4 The Arcas Group, a leading ... Terwindt, MBA as Executive Vice President. He will assume ... previously served as President of Imedex, Inc."Stefan is an ... skills to our company," said Founder and President Jan ...
... Blakely & Company, LLC, a Boston-based life science investment ... III has joined the firm as senior advisor. ... firm on internal and client-related activities including private equity ... particular focus on medical device transactions. "We are ...
... Pharma Limited ("Circ Pharma") and,Elan Corporation plc ("Elan") ... Agreement to develop a chronotherapeutic formulation of Tramadol,for ... , The product incorporates ... dosing. Circ,s technology provides for,minimized delivery to the ...
Cached Biology Technology:The Arcas Group Appoints Executive Vice President 2Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company 2Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc 2
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... Science University (OHSU) and Intel Corp. are teaming ... the field of personalized medicine by dramatically increasing ... patient,s individual genetic profile. Through a multi-year research ... from the two institutions will develop hardware, software ...
... new tool to search for more effective medications and new ... catalogue the entire set of lightweight, carbon-containing molecules that chemists ... has more than 10^60 (that,s 1 with 60 zeroes after ... of the world,s problems have molecular solutions in this chemical ...
... today, a special issue of the Philosophical Transactions ... a major challenge facing our society: feeding a global ... capita food consumption, while preventing widespread ecological and social ... Scientist at The Woods Hole Research Center (WHRC) and ...
Cached Biology News:OHSU teams with Intel to decode the root causes of cancer and other complex diseases 2OHSU teams with Intel to decode the root causes of cancer and other complex diseases 3OHSU teams with Intel to decode the root causes of cancer and other complex diseases 4OHSU teams with Intel to decode the root causes of cancer and other complex diseases 5Scientists map all possible drug-like chemical compounds 2Scientists map all possible drug-like chemical compounds 3Ecology, economy and management of an agro-industrial Amazon frontier 2Ecology, economy and management of an agro-industrial Amazon frontier 3
... Wellpro 384, compatible with ... liquid handling system for ... and accurately prepares large ... The Wellpro also ...
... generation bulk reagent dispenser offering unrivalled level ... and biotech laboratories. Based on the proven ... has been designed for effortless high speed ... multiple plate types including 1536. Through the ...
384 well block MBSr. Robot compatible block ejection mechanism. Stackable. (384 well block - holds 384 well plate)...
... 45° Fixed Angle Rotor ... Centra CL2, Centra CL3CL3R, and ... concentration of sputum samples and ... samples. Provides individual aerosol containment. ...
Biology Products: